tocilizumab: Clinical Trials

502 trials of tocilizumab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

274 completed, 55 recruiting, 52 terminated, 50 unknown. 154 Phase 2, 140 Phase 3, 110 Phase 1, 61 Phase 4, 30 Not applicable.

By phase and status

PhaseTrialsStatus
Phase 2154Completed 55, Terminated 27, Recruiting 24, Active not recruiting 21, Unknown 12, Not yet recruiting 7, Withdrawn 6, Enrolling by invitation 1, Suspended 1
Phase 3140Completed 102, Recruiting 10, Unknown 8, Active not recruiting 7, Terminated 7, Not yet recruiting 5, Withdrawn 1
Phase 1110Completed 49, Active not recruiting 18, Terminated 16, Recruiting 12, Not yet recruiting 6, Unknown 6, Withdrawn 2, Enrolling by invitation 1
Phase 461Completed 31, Unknown 14, Terminated 7, Recruiting 6, Withdrawn 2, Not yet recruiting 1
Not applicable30Completed 17, Recruiting 5, Unknown 4, Terminated 3, Suspended 1
Early Phase 12Active not recruiting 1, Withdrawn 1

Follow tocilizumab: new trials by email Literature Review of tocilizumab trials Research Report on tocilizumab

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Anti-Interleukin-6 (IL6) in Calciphylaxis
Tocilizumab - Calciphylaxis
Phase 1Not yet recruitingBoston Medical Center102027-09-012026-07-16
A Study to Test Obrixtamig Treatment in People With Different Types of Advanced Cancer Who Took Part in a Previous Study With Obrixtamig
Obrixtamig, Ezabenlimab, Atezolizumab - Advanced Cancer
Phase 3Not yet recruitingBoehringer Ingelheim682027-03-042026-11-10
A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis
BMS-986353, Fludarabine, Cyclophosphamide - Systemic Sclerosis
Phase 3Not yet recruitingJuno Therapeutics, Inc., a Bristol-Myers Squibb Company922027-02-032026-09-18
Tocilizumab Combined With First-Line Chemo-Immunotherapy in Metastatic Non-Small Cell Lung Cancer
Tocilizumab, Pembrolizumab, Platinum-Doublet Chemotherapy - Metastatic Non-Small Cell Lung Cancer, Cancer-Associated Weight Loss
Phase 1 / Phase 2Not yet recruitingVA Office of Research and Development432026-12-072026-11-12
TCR1188-ABC Cells in KRAS-mutated Cancers
TCR1188-ABC cells, Fludarabine + Cyclophosphamide combination, Tocilizumab - Cholangiocarcinoma, Colorectal Cancer
Phase 1RecruitingUniversity of Pennsylvania302026-12-012026-10-14
COMparison Between Anakinra and Tocilizumab in NORSE - "COMBAT-NORSE"
Anakinra, Tocilizumab, Standard medical treatment - New Onset Refractory Status Epilepticus, New-Onset Refractory Status Epilepticus
Phase 3Not yet recruitingYale University4382026-12-012026-08-19
Mild-Intensity Whole Body Hyperthermia (WBH) for Major Depressive Disorder
Tocilizumab, Placebo, Whole-Body Hyperthermia - Major Depressive Disorder
Phase 2SuspendedMassachusetts General Hospital352026-12-012025-11-13
Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis
Etanercept, Adalimumab, Upadacitinib - Arthritis, Rheumatoid
RecruitingTufts Medical Center182026-12-012026-11-16
A Clinical Trial of MK-6255 to Treat Endometrial and Ovarian Cancer (MK-6255-001)
MK-6255, CD8 PET Tracer, Acetaminophen - Ovarian Neoplasms, Endometrial Neoplasms
Phase 1Not yet recruitingMerck Sharp & Dohme LLC802026-11-132026-11-16
Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple Myeloma
Cevostamab, Pomalidomide, Dexamethasone - Multiple Myeloma
Phase 2RecruitingHoffmann-La Roche452026-11-032026-11-05
To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis
Cevostamab, Tocilizumab - Lupus Erythematosus, Systemic
Phase 1RecruitingGenentech, Inc.462026-11-022026-11-05
Adding Anakinra and Tocilizumab to Nivolumab and Ipilimumab for the Treatment of Melanoma Patients 50 Years of Age or Older
Anakinra, Biospecimen Collection, Computed Tomography - Melanoma
Phase 1Not yet recruitingUniversity of Southern California402026-11-012026-09-24
Tocilizumab in Chronic Inflammatory CPPD Disease
Tocilizumab, Placebo - Calcium Pyrophosphate Deposition Disease
Phase 2Not yet recruitingAssistance Publique - Hôpitaux de Paris802026-11-012026-11-17
A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006)
MK-1045, Acetaminophen (or similar antipyretic), Diphenhydramine (or similar antihistamine) - Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma
Phase 2RecruitingMerck Sharp & Dohme LLC602026-10-142026-11-13
Clinical Features and Treatment of Systemic JIA in Children
Tocilizumab (Actemra®) - Systemic Juvenile Idiopathic Arthritis (sJIA), Systemic Juvenile Idiopathic Arthritis
Not yet recruitingSohag University502026-10-012026-09-11
Infarct Growth After Intravenous Tocilizumab in Adults With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy - ILLUMINATE
Tociliuzumab, Placebo - Acute Ischemic Stroke
Phase 2 / Phase 3Not yet recruitingOslo University Hospital1562026-09-212026-10-13
Treatment Strategy for Patients With RA-ILD
Tocilizumab, Rituximab (RTX), Methotrexate - Rheumatoid Arthritis Associated Interstitial Lung Disease
Phase 4Not yet recruitingChinese SLE Treatment And Research Group2042026-09-202026-09-03
Atezolizumab, Bevacizumab, and Tocilizumab in Advanced Hepatocellular Carcinoma
Atezolizumab, Bevacizumab, Tocilizumab - Hepatocellular Carcinoma (HCC)
Phase 2Not yet recruitingCHA University512026-09-012026-08-19
A Safety and Tolerability Study of CC- 97540 (BMS-086353) in Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Patients
CC-97540 (BMS-986353), Fludarabine, Cyclophosphamide - AQP4+ NMOSD
Phase 1Not yet recruitingUniversity of Texas Southwestern Medical Center52026-09-012026-07-17
A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma
Elranatamab, Tocilizumab - Multiple Myeloma (MM), Multiple Myeloma Refractory
Phase 2RecruitingSCRI Development Innovations, LLC462026-09-012026-09-04

Showing 20 of 502. Sign in to see all of them.

Conditions studied

Arthritis, Rheumatoid (165)  ·  COVID-19 (46)  ·  Arthritis, Juvenile (24)  ·  Multiple Myeloma (16)  ·  Cytokine Release Syndrome (14)  ·  Giant Cell Arteritis (13)  ·  Inflammation (12)  ·  Lymphoma, Non-Hodgkin (10)  ·  Pneumonia (9)  ·  Carcinoma, Non-Small-Cell Lung (8)  ·  Coronavirus Infections (8)  ·  Breast Neoplasms (7)  ·  Takayasu Arteritis (7)  ·  Lupus Erythematosus, Systemic (6)  ·  Recurrence (6)

Sponsors

Hoffmann-La Roche (170)  ·  Assistance Publique - Hôpitaux de Paris (16)  ·  Chugai Pharmaceutical (13)  ·  Genentech, Inc. (11)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (6)  ·  Copenhagen University Hospital, Rigshospitalet (4)  ·  Massachusetts General Hospital (4)  ·  Oslo University Hospital (4)  ·  Peking Union Medical College Hospital (4)  ·  AO GENERIUM (3)  ·  Bio-Thera Solutions (3)  ·  Brigham and Women's Hospital (3)  ·  Capital Medical University (3)  ·  Duke University (3)  ·  Herlev Hospital (3)

Countries

United States (181)  ·  France (98)  ·  Spain (93)  ·  Italy (65)  ·  United Kingdom (61)  ·  Germany (58)  ·  Canada (55)  ·  Australia (54)  ·  China (52)  ·  Denmark (48)  ·  Belgium (41)  ·  Poland (39)  ·  Brazil (37)  ·  Israel (35)  ·  Netherlands (33)

Top investigators

Takahiro Kakehi (11)  ·  Lindi Jiang, PhD (3)  ·  Oksana A. Markova, MD (3)  ·  Akter Kamal, MD, PhD (2)  ·  Fu-Dong Shi, MD,PhD (2)  ·  Ronald van Vollenhoven, MD, Prof. (2)  ·  William R Drobyski, MD (2)  ·  Yuji Kimura (2)

Results publications

PMID 29244149, PMID 30649524, PMID 22491018, PMID 24429164, PMID 32453485, PMID 18358927, PMID 23765873, PMID 24634205, PMID 24786929, PMID 27909081, PMID 28376912, PMID 28955499, PMID 30590833, PMID 30824645, PMID 31043095, PMID 32508063, PMID 32912276, PMID 33201228, PMID 33294861, PMID 33394942, PMID 33506875, PMID 34473343, PMID 34612846, PMID 37328287, PMID 37489818, PMID 40198544, PMID 40749164, PMID 42283231, PMID 42836590, PMID 14558057, PMID 16368644, PMID 17487675, PMID 1750226, PMID 18358926, PMID 18625622, PMID 18821691, PMID 19297346, PMID 20039425, PMID 21360490, PMID 21949007, PMID 22373834, PMID 22397953, PMID 22562983, PMID 22674883, PMID 22753773, PMID 22907572, PMID 22972745, PMID 23252525, PMID 23305631, PMID 23322466

NIH funding

2023 (13), 2009 (11), 2008 (8), 2016 (7), 2018 (7), 2017 (6), 2019 (6), 2014 (5), 2015 (5), 2025 (5), P30CA138292 (2), 1UG3CA283652-01 (1), K08HL143189 (1), P30CA008748 (1), P30CA014089 (1)